Publications dans lesquelles il/elle collabore avec Karmele Valencia Leoz (19)

2024

  1. Protein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility Assessment

    Archivos de Bronconeumologia

2023

  1. Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer

    Cancers, Vol. 15, Núm. 12

  2. Estrogen Receptor and Immune Checkpoint Inhibitors: New Partners in Lung Cancer?

    Clinical cancer research : an official journal of the American Association for Cancer Research

  3. PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

    Cancer Research, Vol. 83, Núm. 15, pp. 2513-2526

2022

  1. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

  2. DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity

    The Journal of experimental medicine, Vol. 219, Núm. 12

  3. Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer

    Journal for immunotherapy of cancer, Vol. 10, Núm. 8

  4. Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma

    DMM Disease Models and Mechanisms, Vol. 15, Núm. 1

  5. YES1 Is a Druggable Oncogenic Target in SCLC

    Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1387-1403

2021

  1. Cancer epigenetic biomarkers in liquid biopsy for high incidence malignancies

    Cancers, Vol. 13, Núm. 12

  2. Exosomes in liquid biopsy: The nanometric world in the pursuit of precision oncology

    Cancers, Vol. 13, Núm. 9

  3. Molecular biomarkers in early stage lung cancer

    Translational Lung Cancer Research, Vol. 10, Núm. 2, pp. 1165-1185

2020

  1. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade

    Nature cancer, Vol. 1, Núm. 1, pp. 75-85

2019

  1. Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1

    Scientific Reports, Vol. 9, Núm. 1

  2. YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

    American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899

2014

  1. RHOB influences lung adenocarcinoma metastasis and resistance in a host-sensitive manner

    Molecular Oncology, Vol. 8, Núm. 2, pp. 196-206

2012

  1. Estudio del valor pronóstico de nuevos mediadores del proceso metastásico en el cáncer de pulmón

    Anales del sistema sanitario de Navarra, Vol. 35, Núm. 1, pp. 178-179

  2. Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis

    Clinical Cancer Research, Vol. 18, Núm. 4, pp. 969-980

  3. Receptor of activated protein C promotes metastasis and correlates with clinical outcome in lung adenocarcinoma

    American Journal of Respiratory and Critical Care Medicine, Vol. 186, Núm. 1, pp. 96-105